Ignite Creation Date:
2024-05-06 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04722887
Status:
RECRUITING
Last Update Posted:
2024-06-06
First Post:
2021-01-20
Brief Title:
A Study to Evaluate Safety Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous Human 15 in Participants With Alpha1-Antitrypsin Deficiency
Sponsor:
Grifols Therapeutics LLC
Organization:
Grifols Therapeutics LLC
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Alpha1-Antitrypsin Deficiency |
Keywords:
| Name | View |
|---|---|
| Molecular Mechanisms of Pharmacological Action | View |
| Pulmonary Emphysema | View |
| Alpha-1 Antitrypsin Deficiency | View |
| AATD | View |
| Alpha-1 PI Deficiency | View |
| Alpha-1 Proteinase Inhibitor | View |
| Emphysema | View |
| Pathologic Processes | View |
| Pulmonary Disease Chronic Obstructive | View |
| Lung Diseases Obstructive | View |
| Lung Diseases | View |
| Respiratory Tract Diseases | View |
| Liver Diseases | View |
| Digestive System Diseases | View |
| Genetic Diseases Inborn | View |
| Subcutaneous Emphysema | View |
| Alpha1-Antitrypsin | View |
| Trypsin Inhibitors | View |
| Serine Proteinase Inhibitors | View |
| Protease Inhibitors | View |
| Enzyme Inhibition | View |